Karen Facey worked as a senior statistician in pharma and medicines regulation before moving to Scotland in 2000 to setup the first national HTA agency. Since 2003, she has been an independent consultant working with all stakeholders on matters related to HTA, real-world data and patient involvement. She has also served for 10 years on the governing board of regional and national health boards in Scotland and is a member of the national non-medicines appraisal committee. Karen is now an senior HTA advisor to the RWE4Decisions learning network and the Guidelines for RWE Generation and SUSTAIN-HTA projects via the Universities of Oxford and Utrecht. She is also a member of the Myeloma Patients Europe patient evidence research committee.